Table 4 Adverse events of any grade seen in > 5% of patients in either protocol arm
|  | Letrozole, n = 25 | Letrozole/Bevacizumab, n = 50 | ||
|---|---|---|---|---|
| Â | Number of patients (percent) | |||
Adverse events | Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 |
 Hot flashes | 7 (28) | 0 | 9 (18) | 0 |
 Arthralgia/joint stiffness | 6 (24) | 2 (8) | 13 (26) | 2 (4) |
 Fatigue | 4 (16) | 0 | 7 (14) | 1 (2) |
 Myalgias/cramps | 3 (12) | 0 | 3 (6) | 0 |
 Nausea/vomiting | 2 (8) | 0 | 1 (2) | 0 |
 Night sweats | 2 (8) | 0 | 2 (4) | 0 |
 Mood swings/anxiety/agitation | 1 (4) | 0 | 3 (6) | 0 |
 Vaginal dryness | 1 (4) | 0 | 3 (6) | 0 |
 Hypertension | 1 (4) | 0 | 16 (32) | 4 (8) |
 Hemorrhagic and thrombotic events | 0 | 0 | 8 (16) | 3 (6) |
 Headache | 1 (4) | 0 | 7 (14) | 0 |
 Proteinuria | 0 | 0 | 5 (10) | 2 (4) |
 Dyspnea | 1 (4) | 0 | 5 (10) | 0 |
 Skin (rash, discoloration, pruritus) | 2 (8) | 0 | 4 (8) | 0 |
 Lower extremity edema | 0 | 0 | 3 (6) | 0 |